Literature DB >> 33398683

Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma in a Geriatric Patient-Report of a Rare Case.

Ahitagni Biswas1, Sorun Shishak2, Swarnaditya Roy2, Aanchal Kakkar3.   

Abstract

Sinonasal anaplastic lymphoma kinase(ALK)-negative anaplastic large cell lymphoma(ALCL) without nodal involvement is exceedingly rare and the rarity of this tumor often engenders diagnostic dilemma. It has been mostly reported in pediatric, adolescent and young adult patients, mostly of Asian origin. A 70-year-old female patient presented with a mass in the left nasal cavity causing nasal obstruction for 5 months. On clinical and radiological examination, there was a 5.7 cm mass in the left nasal cavity, completely obliterating the left ethmoid sinus. Biopsy from the nasal mass showed a poorly differentiated malignant tumour with large cells arranged in sheets. On immunohistochemistry, the tumour cells were positive for leukocyte common antigen(LCA), CD30, CD43, BCL6 and focally for CD5, TIA1, granzyme B and epithelial membrane antigen(EMA), and were negative for CD56, EBV-LMP1, CD79a, PAX5, myeloperoxidase, CD34, CD7, CD4, CD8, CD138, ALK and p63, suggestive of ALK-negative ALCL. Rest of the lymphoma work-up was essentially normal and she had stage IE disease. She was treated with prephase chemotherapy (Vincristine and Prednisolone) followed by 4 cycles of CEOP[Cyclophosphamide, Etoposide (from 2nd cycle onwards), Vincristine and Prednisolone] regimen and local radiotherapy (36 Gy/20 fractions/4 weeks) by intensity modulated radiotherapy(IMRT) technique resulting in complete clinical and radiological response. At last follow-up visit, 15 months from the initial diagnosis, she was alive and disease free. Sinonasal ALK-negative ALCL is a rare tumor which can be effectively treated with a combination of multi-agent CHOP/CHOP-like regimen and local conformal radiotherapy in geriatric patients.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Anaplastic large cell lymphoma; Anaplastic lymphoma kinase; Intensity modulated radiotherapy; Lymphoma; Sinonasal

Mesh:

Substances:

Year:  2021        PMID: 33398683      PMCID: PMC8633218          DOI: 10.1007/s12105-020-01276-3

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  23 in total

1.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K Dittmer; D N Shapiro; A T Look; D L Saltman
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

Review 2.  ALCL by any other name: the many facets of anaplastic large cell lymphoma.

Authors:  Lina Irshaid; Mina L Xu
Journal:  Pathology       Date:  2019-11-06       Impact factor: 5.306

3.  Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.

Authors:  Marie-Cécile Le Deley; Angelo Rosolen; Denise M Williams; Keizo Horibe; Grazyna Wrobel; Andishe Attarbaschi; Jozsef Zsiros; Anne Uyttebroeck; Ildiko M Marky; Laurence Lamant; Wilhelm Woessmann; Marta Pillon; Rachel Hobson; Audrey Mauguen; Alfred Reiter; Laurence Brugières
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma.

Authors:  Xi-Mei Zhang; Ye-Xiong Li; Wei-Hu Wang; Jing Jin; Shu-Lian Wang; Yue-Ping Liu; Yong-Wen Song; Hua Ren; Hui Fang; Li-Qiang Zhou; Bo Chen; Shu-Nan Qi; Qing-Feng Liu; Ning-Ning Lu; Xin-Fan Liu; Zi-Hao Yu
Journal:  Eur J Haematol       Date:  2013-01-27       Impact factor: 2.997

5.  Anaplastic large cell lymphoma: twenty-five years of discovery.

Authors:  Marsha C Kinney; Russell A Higgins; Edward A Medina
Journal:  Arch Pathol Lab Med       Date:  2011-01       Impact factor: 5.534

6.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.

Authors:  T Iwahara; J Fujimoto; D Wen; R Cupples; N Bucay; T Arakawa; S Mori; B Ratzkin; T Yamamoto
Journal:  Oncogene       Date:  1997-01-30       Impact factor: 9.867

7.  Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Young Adult-Report of a Rare Case.

Authors:  Ahitagni Biswas; Bharti Devnani; Shipra Agarwal; Mehar Chand Sharma; Atul Sharma
Journal:  J Adolesc Young Adult Oncol       Date:  2019-04-17       Impact factor: 2.223

8.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors:  Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2008-04-02       Impact factor: 22.113

9.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Authors:  Edgardo R Parrilla Castellar; Elaine S Jaffe; Jonathan W Said; Steven H Swerdlow; Rhett P Ketterling; Ryan A Knudson; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; George Vasmatzis; Sarah E Gibson; Sarah Ondrejka; Alina Nicolae; Karen L Grogg; Cristine Allmer; Kay M Ristow; Wyndham H Wilson; William R Macon; Mark E Law; James R Cerhan; Thomas M Habermann; Stephen M Ansell; Ahmet Dogan; Matthew J Maurer; Andrew L Feldman
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

10.  Anaplastic lymphoma kinase-positive large cell lymphoma of the anterior skull base: Report of an unusual case and review of the literature.

Authors:  Pouya Jamshidi; James Y Chen; Huan-You Wang; Clark C Chen
Journal:  Surg Neurol Int       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.